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Background. Patients presenting with acutely decompensated heart failure (ADHF) and positive circulating cardiac troponins were
found to be a high-risk cohort. The advent of high-sensitive troponins resulted in a detection of positive troponins in a great
proportion of heart failure patients. However, the pathophysiological significance of this phenomenon is not completely clear.
Objectives.The aim of this study is to determine the early evolution and clinical significance of high-sensitivity troponin T (hsTnT)
in ADHF. Methods. Retrospective, secondary analysis of a prospective study including 100 patients with ADHF. Results. Globally,
high-sensitivity troponin T decreased from day 1 to day 3 (𝑃 = 0, 039). However, in the subgroup of patients who remained
decompensated no significant differences in hsTnT from day 1 to day 3 were observed (𝑃 = 0, 955), whereas in successfully
compensated patients a significant reduction in hsTnT levels was observed (𝑃 = 0, 025). High-sensitivity troponin T decrease was
correlated with NTproBNP reduction (𝑃 = 0, 007). Patients with hsTnT increase had longer length of stay (𝑃 = 0, 033).Conclusions.
Episodes of ADHF are associated with transient increases in the blood levels of hsTnT that are reduced with effective acute episode
treatment. The decrease in hsTnT can translate less myocardial damage along with favourable ADHF treatment.
1. Introduction
Patients presenting with acutely decompensated heart failure
(ADHF) and positive circulating cardiac troponins were
found to be a high-risk cohort, requiring greater use of hos-
pital resources and having increased risk of in-hospital mor-
tality [1]. Measurement of cardiac troponins in this setting
adds important prognostic information and should be con-
sidered as part of an early assessment of risk [1, 2].
Detectable troponins, even in the absence of acute coro-
nary syndrome, are associatedwith impaired hemodynamics,
progressive decline in left ventricular systolic function, and
shortened survival [3–5].
Recent improvements in the sensitivity of troponin assays
added additional challenges in the interpretation of these
biomarkers in heart failure (HF). The increasing sensitivity
of more contemporary assays has resulted in the detection
of circulating troponin in a progressively greater proportion
of HF patients. This phenomenon has led to increasing
uncertainty about the clinical interpretation of troponin
data from contemporary assays, particularly in patients with
ADHF, since a substantial proportion of these patients have
elevations of circulating troponins [1, 6, 7].
The aim of this study is to determine the early evolution,
associations, and correlations of high-sensitivity troponin T
(hsTnT) in ADHF.
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2. Methods
2.1. Study Design. We analysed a database from a previous
con-ducted prospective, interventional trial that we per-
formed [8]. In that study we enrolled 100 consecutive
patients who presented in a Portuguese tertiary hospital with
ADHF, between February 2012 and February 2013. They
were assigned in a sequential 1 : 1 ratio to spironolactone plus
standard ADHF therapy or standard ADHF therapy alone.
Patients were eligible for enrollment if they presented with
decompensation of chronic HF with symptoms leading to
hospitalization. ADHF was diagnosed on the basis of the
presence of history of chronic HF and at least one symptom
(dyspnea, orthopnea, or edema) and one sign (rales, periph-
eral edema, ascites, or pulmonary vascular congestion on
chest radiography). Exclusion criteria were chronic use of
mineralocorticoid receptor antagonists (MRAs), cardiac
surgery within 60 days of enrollment, cardiac mechanical
support, cardiac resynchronization-therapywithin the last 60
days, comorbid conditions with an expected survival of less
than 6 months, acute MI at time of hospitalization, hemo-
dynamically significant uncorrected primary cardiac valvular
disease, patients requiring intravenous vasodilators or ino-
tropic agents, supine systolic arterial blood pressure
<90mmHg, plasma creatinine (pCr) level >1,5mg/dL, serum
potassium level >5,0mmol/L, hemoglobin (HgB) level
<9 g/dL, and sepsis.
Institutional review board or ethics committee approval
was obtained. All patients providedwritten informed consent
to participate in the study.
2.2. Study Assessments. Patient’s clinical assessment includ-
ing physical examination was prospectively recorded daily by
the same assistant physician.
Medications and respective dosages were prospectively
recorded by the investigators according to the assistant
physician prescriptions.
Blood and spot urine samples were collected in the first
24 hours (h) after admission (day 1) of the patient to the hos-
pital.The day 3 samples were collected between 72 and 96 h of
hospitalization. An assessment of biomarkers, including
pCr, plasma urea (pUr), electrolytes, N-terminal probrain
natriuretic peptide (NTproBNP), and hsTnT, was performed
at a central core laboratory at day 1 and day 3. Clin-
ical assessment and routine analyses were performed daily
during hospital stay. Estimated glomerular filtration rate
(eGFR) was determined using the chronic kidney disease
epidemiology collaboration (CKD-EPI) equation [8]. All
patients performed a transthoracic echocardiography within
72 hours upon admission. Ejection fraction (EF) was calcu-
lated according to biplane Simpson method.
High-sensitive troponin T was measured using COBAS
Troponin T hs (highly sensitive) STAT (short turn-around
time) (Roche Diagnostics). According to the manufacturer a
positive hsTnT test was considered when the value was above
the upper reference limit (99th percentile) of 0,014 ng/mL.
2.3. Variable Definitions. We studied hsTnT regarding the
following covariates: comorbidities such as diabetes mellitus
(DM), chronic obstructive pulmonary disease (COPD), and
sleep apnea; bodymass index (BMI); heart rate (HR); systolic
blood pressure (SBP); atrial fibrillation (AF); HF etiology;
echocardiographic parameters such as EF; furosemide dose,
proportion of patients on angiotensin converting enzyme
inhibitors (ACEi), beta-blockers (BB), and spironolactone;
pCr, pUr, NTproBNP, sodium, and potassium; HgB and
serum albumin.
In order to determine the differences in hsTnT concen-
tration between patients with faster diuretic response and
patients with slower diuretic response after 3 days of inpatient
treatment, patients were considered faster diuretic respon-
ders if they had decreased intravenous (i.v.) furosemide
dose or switched to oral furosemide in the first three days
of in-hospital treatment. On the other hand, patients were
considered to be slower diuretic responders if the assistant
physician increased or maintained i.v. furosemide dosage
after three days of in-hospital treatment.
2.4. Statistical Analysis. Normally distributed continuous
variables are expressed as mean ± standard deviation (SD),
and skewed distributions are presented asmedian (interquar-
tile range (IQR)).
Categorical variables are expressed in absolute numbers
(no.) and proportions (%).
Comparison between groups was performed using para-
metric, nonparametric tests, or chi-square tests, as appropri-
ate. Significant association was defined by a probability (𝑃)
value ≤ 0,05.
The positively skewed distributions were log transformed
for analysis.
Correlations of log hsTnT were first examined by single
variable linear or logistic regression and presented as non-
adjusted coefficient (NAC) and 95% confidence interval
[
95%CI]. Factors with a 𝑃 value ≤ 0,05 by single variable
regression analyses were included in a multivariable linear
regression model, presented as adjusted coefficient (AC)
[
95%CI].
Statistical analysis was performed using SPSS software
(version 19, Chicago, IL, USA).
3. Results
3.1. Baseline Characteristics and Early Changes. Mean ± SD
age of the 100 patients admitted due to ADHF was 76 ± 10,9
years. Thirty-nine (39%) patients were male; 50 patients had
documented ischemic heart disease (IHD); 59 had AF; and
mean ± SD EF (%) was 43,46 ± 11,73 (Table 1). All patients
were admitted in New York Heart Association (NYHA) class
IV. Patient characteristics, medications, and comparison of
lab results between admission day (day 1) and the third day
of inpatient treatment are shown in Table 1.
Globally, high-sensitivity troponin T was likely to
decrease from day 1 to day 3 (median [IQR], 0,033 [0,019–
0,050] versus 0,030 [0,018–0,051], 𝑃 = 0, 039) (Table 1).
However, in the subgroup of patients considered to have
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Table 1: Population characteristics and comparison of clinical variables, laboratory results, and medications between admission day (day 1)
and day 3.
Age (yrs) 76,0 ± 10,88
Male sex—% 39
Diabetes mellitus—% 45
Glycated HgB (%) 7,02 ± 0,96
COPD—% 17
Dementia—% 12
Sleep apnea—% 18
Noninvasive ventilation—% 17
Ischemic heart disease—% 50
Atrial fibrillation—% 59
LV ejection fraction (%) 43,46 ± 11,73
LV ejection fraction ≥40%—% 68
Day 1 Day 3 𝑃 value
Body mass index (Kg/m2) 29,44 ± 6,17 28,35 ± 6,23 <0,001
Heart rate (bpm) 93,65 ± 24,35 76,41 ± 11,96 <0,001
SBP (mmHg) 139,79 ± 25,86 121,97 ± 16,2 <0,001
Plasma creatinine (mg/dL) 1,04 [0,89–1,31] 1,06 [0,85–1,40] 0,082∗
eGFR (mL/min/1,73m2) 58,0 [44,0–72,0] 58,0 [39,25–72,75] 0,171∗
Plasma urea (mg/dL) 55,21 ± 20,84 62,3 ± 25,47 0,001
Serum potassium (mmol/L) 4,03 ± 0,51 4,04 ± 0,54 0,95
Serum sodium (mmol/L) 140,54 ± 4,38 140,68 ± 3,95 0,72
Hemoglobin (g/dL) 12,43 ± 2,07 — —
Albumin (mg/dL) 3,68 ± 0,40 — —
NTproBNP (pg/mL) 2750 [1672–6032] 1835 [902–3837] <0,001∗
hsTnT (ng/mL) 0,033 [0,019–0,050] 0,030 [0,018–0,051] 0,039∗
IV furosemide—% 100 37 <0,001∗∗
IV furosemide dose (mg/d) 75,80 ± 21,52 67,57 ± 25,54 0,001
Oral furosemide—% 0 63 —
Oral furosemide dose (mg/d) 0 74,6 ± 28,1 —
Furosemide dose reduction or oral route—% — 84 —
ACEi—% 44 61 <0,001∗∗
Ramipril Eq. dose (mg/d) 3,15 ± 2,04 3,36 ± 2,14 0,474
Beta-blocker—% 37 57 <0,001∗∗
Bisoprolol Eq. dose (mg/d) 3,01 ± 1,08 2,96 ± 1,89 0,474
Spironolactone—% 50 50 1∗∗
Spironolactone dose (mg/d) 94,50 ± 23,31 62,74 ± 24,33 <0,001
Continuous variables are presented as mean value ± standard deviation [SD], 𝑃 value or median [interquartile range (IQR)], 𝑃 value. Categorical variables are
presented as % of total (100 patients), 𝑃 value.
∗Nonparametric paired sample test; ∗∗chi-square test.
COPD: chronic obstructive pulmonary disease; LV: left ventricular; eGFR: estimated glomerular filtration rate; NTproBNP: N-terminal probrain natriuretic
peptide; hsTnT: high sensitivity troponin T; IV: intravenous; ACEi: angiotensin converting enzyme inhibitors.
slower diuretic response no significant differences in hsTnT
from day 1 to day 3 were observed (median [IQR], from
0,046 [0,033–0,087] to 0,055 [0,032–0,072], 𝑃 = 0, 955),
whereas in the group of patients considered to have a faster
diuretic response a significant reduction in hsTnT levels was
observed (median [IQR], from 0,032 [0,017–0,048] to 0,028
[0,017–0,045], 𝑃 = 0, 025) (Table 2 and Figure 1). The hsTnT
variation did not differ between groups (median [IQR],
−0,0005 [−0,043 to 0,004] versus −0,0010 [−0,020 to 0,002],
𝑃 = 0, 51) (Table 2). The majority of patients with negative
hsTnT at day 1 remained negative at day 3 (76,9%). On the
other hand only a small proportion (3,1%) of patients with
positive hsTnT at day 1 turned negative at day 3 (Table 3).
3.2. High-Sensitivity Troponin T Correlations. Bivariate anal-
ysis of hsTnT at day 1 found positive correlations with day
1 Log NTproBNP (NAC [
95%CI], 0,481 [0,267 to 0,574],
𝑃 < 0, 001), pUr (NAC [
95%CI], 0,309 [0,002 to 0,009],
𝑃 = 0,002), and Log pCr (NAC, [
95%CI], 0,345 [0,500 to
1,704], 𝑃 < 0, 001). A negative correlation was found with
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Table 2: Comparison of TnT levels between patients who responded to diuretic therapy versus patients who needed to increase diuretic dose.
Furosemide maintenance or increase
(𝑛 = 16)
Furosemide decrease or oral administration
(𝑛 = 84)
𝑃 value
Between groups
hsTnT (ng/mL)
Day 1 0,046 [0,033 to 0,087] 0,032 [0,017 to 0,048] 0,026∗
Day 3 0,055 [0,032 to 0,072] 0,028 [0,017 to 0,045] 0,004∗
ΔhsTnT −0,0005 [−0,043 to 0,004] −0,0010 [−0,020 to 0,002] 0,51∗
𝑃 value within group 𝑃 value within group
0,955∗ 0,025∗
Continuous variables are presented as median [interquartile range (IQR)], 𝑃 value. ∗Nonparametric test.
hsTnT: high-sensitivity troponin T.
Table 3: Comparison of hsTnT values below (negative) and above (positive) the 99th percentile (≥0,014 ng/mL).
Day 1 Total 𝑃 value
Negative hsTnT—no. (%) Positive hsTnT—no. (%)
Day 3
Negative hsTnT—no. (%) 10 (76,9) 3 (3,4) 13 (13) <0,001∗∗
Positive hsTnT—no. (%) 3 (23,1) 84 (96,6) 87 (87) <0,001∗∗
Total 13 (13) 87 (87) 100
∗∗Chi-square test. Legend: hsTnT: high-sensitivity troponin T.
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Figure 1: Differences in hsTnT between faster diuretic responders
and slower diuretic responders at day 1 and day 3. hsTnT: high-
sensitivity troponin T (ng/mL).
Log eGFR (NAC [
95%CI], −0,275 (−1,231 to −0,216), 𝑃 =
0, 006). Day 3 hsTnT was also positively correlated with day
3 Log NTproBNP (NAC [
95%CI], 0,486 [0,218 to 0,464], 𝑃 <
0, 001) and Log pCr (NAC, [
95%CI], 0,439 [0,630 to 1,503],
𝑃 < 0, 001) and negatively correlated with Log eGFR (NAC
[
95%CI], −0,399 (−1,232 to −0,455), 𝑃 = 0, 006) (Table 4).
High-sensitivity troponin T decrease was correlated with
NTproBNP reduction (NAC [
95%CI], 0,267 [0,044 to 0,276],
𝑃 = 0, 007) (Table 4 and Figure 2). By multivariate analysis,
hsTnT correlated with NTproBNP at day 1 and day 3 (AC
[
95%CI], 0,400 [0,185 to 0,513], 𝑃 < 0, 001, and 0,381 [0,146
to 0,389], 𝑃 < 0, 001, resp.) (Table 4).
r = 0,267; P = 0,007
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Figure 2: Correlation between ΔLog hsTnT and ΔLog
NTproBNP. hsTnT: high-sensitivity troponin T (ng/mL);
NTproBNP: N-terminal probrain natriuretic peptide (pg/mL);
Δ: changes between day 3 and day 1 (day 3–day 1).
3.3. Determinants of hsTnT Change. High-sensitivity tro-
ponin T was transformed according to the pattern of change
(decrease or increase) during the first 3 days of treatment
(Table 5).
Patients with hsTnT increase had lower NTproBNP
decrease (median [IQR], −1167 [−2337 to −367] versus −379
[−1273 to 319,5], 𝑃 = 0, 003), had longer length of stay
(median [IQR], 8 [6 to 11] versus 9 [7 to 12], 𝑃 = 0, 033),
and had higher proportion of AF (49,2% versus 75,7%,
𝑃 = 0, 009). Diuretic dosages, other HF medications, renal
function, and length of stay did no differ between groups
(Table 5).
4. Discussion
The major finding of this study is that episodes of ADHF
are associated with transient increases in the blood levels of
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Table 4: Associations with log hsTnT at day 1, day 3 and changes between day 1 and day 3 (Δ).
Nonadjusted coefficient for
log hsTnT 95%CI 𝑃 value
Adjusted coefficient for
log hsTnT 95%CI 𝑃 Value
Age 0,119 −0,001 to 0,005 0,240
Male sex −0,066 −0,086 to 0,043 0,515
DM 0,095 −0,033 to 0,093 0,349
HgBA1c 0,058 −0,046 to 0,067 0,707
LVEF 0,089 −0,001 to 0,004 0,376
Ischemic HF −0,078 −0,087 to 0,038 0,442
Beta-blocker −0,004 −0,065 to 0,062 0,969
ACEi 0,023 −0,057 to 0,072 0,820
Spironolactone −0,116 −0,099 to 0,026 0,251
BMI
Day 1 −0,205 −0,025 to 0,000 0,042
Day 3 −0,087 −0,016 to 0,006 0,391
ΔBMI −0,008 −0,019 to 0,018 0,937
HR
Day 1 0,063 −0,002 to 0,004 0,533
Day 3 −0,078 −0,008 to 0,004 0,438
ΔHR 0,013 −0,001 to 0,001 0,899
SBP
Day 1 0,102 −0,001 to 0,004 0,314
Day 3 0,098 −0,002 to 0,006 0,333
ΔSBP 0,207 0,000 to 0,003 0,039
logNTproBNP
Day 1 0,481 0,267 to 0,574 <0,001 0,400 0,185 to 0,513 <0,001
Day 3 0,486 0,218 to 0,464 <0,001 0,381 0,146 to 0,389 <0,001
Δ logNTproBNP 0,267 0,044 to 0,276 0,007 — — —
logAlbuminuria
Day 1 0,131 −0,035 to 0,172 0,193
Day 3 0,220 0,012 to 0,203 0,028 0,088 −0,041 to 0,128 0,311
Δ logAlbuminuria 0,099 −0,038 to 0,113 0,325
log eGFR
Day 1 −0,275 −1,231 to −0,216 0,006 0,165 −0,503 to 1,372 0,360
Day 3 −0,399 −1,232 to −0,455 <0,001 0,034 −0,812 to 0,957 0,870
Δ log eGFR 0,068 0,203 to 0,413 0,502
log pCr
Day 1 0,345 0,500 to 1,704 <0,001 0,270 −0,224 to 1,951 0,118
Day 3 0,439 0,630 to 1,503 <0,001 0,256 −0,393 to 1,641 0,226
Δ log pCr −0,040 −0,443 to 0,297 0,696
pUrea
Day 1 0,309 0,002 to 0,009 0,002 0,116 −0,002 to 0,007 0,342
Day 3 0,382 0,003 to 0,008 <0,001 0,121 −0,002 to 0,005 0,335
ΔpUrea −0,172 −0,003 to 0,000 0,087
Albumin at day 1 −0,049 −0,099 to 0,060 0,626
Hemoglobin at day 1 0,076 −0,009 to 0,021 0,451
Day 1 values are compared with day 1 hsTnT; day 3 values are compared with day 3 hsTnT; Δ, age, sex, DM, HgBA1c, LVEF, ischemic HF, and medications are
compared with changes (Δ) in hsTnT between day 1 and day 3 (day 3–day 1).
DM: diabetes mellitus; HgBA1c: glycated hemoglobin; LVEF: left ventricular ejection fraction; HF: heart failure; ACEi: angiotensin converting enzyme
inhibitors; BMI: body mass index; HR: heart rate; SBP: systolic blood pressure; NTproBNP: N-terminal probrain natriuretic peptide; hsTnT: high sensitivity
troponin T; eGFR: estimated glomerular filtration rate; pCr: plasma creatinine; pUrea: plasma urea; Δ: changes between day 3 and day 1 (day 3–day 1).
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Table 5: Determinants of hsTnT dichotomic changes.
hsTnT
𝑃 value
Decrease (𝑛 = 63) Increase (𝑛 = 37)
Age (years) 75,94 ± 11,92 76,11 ± 8,97 0,940
Male sex—no. (%) 22 (34,9) 17 (45,9) 0,275∗∗
DM—no. (%) 24 (38,1) 21 (56,8) 0,070∗∗
HGA1c (%) 6,93 ± 0,94 7,13 ± 1,00 0,475
Sleep apnea—no. (%) 7 (36,8) 11 (44) 0,632∗∗
NIV—no. (%) 10 (15,9) 7 (18,9) 0,695∗∗
IHD—no. (%) 32 (50,8) 18 (48,6) 0,836∗∗
AF—no. (%) 31 (49,2) 28 (75,7) 0,009∗∗
LVEF (%) 43,37 ± 12,68 43,62 ± 10,08 0,917
LVEF ≥40%—no. (%) 41 (65,1) 26 (70,3) 0,594∗∗
HgB (g/dL) 12,32 ± 1,95 12,62 ± 2,28 0,478
Albumin (mg/dL) 3,68 ± 0,41 3,67 ± 0,39 0,924
ΔBMI (Kg/m2) −1,08 ± 1,70 −1,10 ± 1,76 0,964
ΔHR (bpm) −17,05 ± 20,71 −17,57 ± 29,15 0,917
ΔSBP (mmHg) −18,56 ± 23,32 −16,57 ± 27,63 0,702
ΔpCr (mg/dL) 0,03 [−0,1 to 0,18] 0,02 [−0,06 to 0,11] 0,803∗
ΔeGFR (mL/min/1,73m2) −2,0 [−9,0 to 7,0] −1,0 [−11,0 to 6,0] 0,937∗
ΔpUrea (mg/dL) 7,40 ± 20,59 6,59 ± 20,65 0,851
ΔNTproBNP (pg/mL) −1167 [−2337 to −367] −379 [−1273 to 319,5] 0,003∗
ΔhsTnT (ng/mL) −0,004 [−0,014 to −0,001] 0,004 [0,002 to 0,009] <0,001∗
ΔAlbuminuria (mg/g) −6,10 [−38,50 to 2,40] −23,70 [−90,75 to 11,05] 0,337∗
IV furosemide at day 1 (mg) 78,83 ± 21,61 74,05 ± 21,53 0,537
IV furosemide dose
Maintenance or increase at day 3—no. (%) 9 (14,3) 7 (18,9) 0,542∗∗
ACEi—no. (%) 30 (47,6) 14 (37,8) 0,341∗∗
Beta-blocker—no (%) 22 (34,9) 15 (40,5) 0,574∗∗
Spironolactone—no. (%) 30 (47,6) 20 (54,1) 0,534∗∗
Length of stay (days) 8,0 [6,0 to 11,0] 9,0 [7,0 to 12,0] 0,033∗
Continuous variables are presented as mean value ± standard deviation [SD], 𝑃 value or median [interquartile range (IQR)], 𝑃 value. Categorical variables are
presented as absolute number (%), 𝑃 value.
∗Nonparametric paired sample test; ∗∗chi-square test.
DM: diabetes mellitus; HgBA1c: glycated hemoglobin; NIV: noninvasive ventilation; IHD: ischemic heart disease; AF: atrial fibrillation; HgB: hemoglobin;
BMI: body mass index; HR: heart rate; SBP: systolic blood pressure; eGFR: estimated glomerular filtration rate; pCr: plasma creatinine; pUrea: plasma urea;
NTproBNP: N-terminal probrain natriuretic peptide; hsTnT: high sensitivity troponin T; IV: intravenous; ACEi: angiotensin converting enzyme inhibitors; Δ:
changes between day 3 and day 1 (day 3–day 1).
hsTnT that are reducedwith acute episode effective treatment.
This statement is corroborated by the higher levels of hsTnT
in patients who maintained or increased i.v. furosemide dose
after 3 days of hospitalization, by a decrease in hsTnT levels
in patients with faster response to diuretic therapy, by the
correlation between troponin T decrease and NTproBNP
reduction, and by the longer length of stay and lower decrease
inNTproBNP levels in the group of patients who had increase
in hsTnT from day 1 to day 3.
Improvements in analytical sensitivity have transformed
circulating troponin from a biomarker that was only detect-
able in a minority of patients to one that is detectable in the
vast majority of patients with HF [1]. The high sensitivity
of the test can detect very small changes in the circulating
troponin levels [1, 7], providing a potential explanation for
the high proportion of patients who remained above the 99th
percentile after 3 days of treatment.
In our study over 80% of the patients had hsTnT levels
above the 99th percentile; this prevalence of detectable hsTnT
was higher than in previously published reports [1–3, 6,
9, 10]. The most likely explanation for this finding is the
type of tests, assay platforms, and the cutoff limits used in
those studies. For example, the acute decompensated heart
failure national registry (ADHERE) study used a higher
cutoff limit of 0,1 ng/mL and they did not control the assay
platform [1], and in the enhanced feedback for effective
cardiac treatment (EFFECT) study the cutoff limit used was
0,5 ng/mL3. However, in the another study by Metra et al.
[6] the used cutoff was 0,01 ng/mL where levels above this
value were considered abnormal. In that study, 51 (48%)
of the 107 patients discharged alive from the hospital had
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detectable troponin in at least one measurement. Despite the
differences in the type of test and assay platform, the cutoff
limit was similar to the cutoff used in our study. One possible
explanation for this discrepancy is the mean ± SD age of the
patients included in the present study. Our patients are older
than patients included in the study by Metra et al. (76 ± 10,9
versus 66 ± 13 years, resp.). Troponin levels are likely to have
a Gaussian or near Gaussian distribution, with higher levels
found in older age groups [11].
Elevations in baseline troponin levels were demonstrated
to be independent predictors of events during the acute
hospitalization (worsening or persistent HF, death, and
increased length of stay) and also independent predictors
of postdischarge outcomes [3, 6, 9, 12–14]. In our study,
an increase in hsTnT levels was also associated with longer
length of stay consistent with the previous cited reports.
Changes in troponin status during initial treatment for
ADHF have been proposed as potentially important targets
for drug development [15]. In the biomarker analysis from the
Relaxin in acute heart failure (RELAX-AHF) development
program [16], changes in markers of cardiac (hsTnT), renal
(pCr and cystatin-C), and hepatic (aspartate transaminase
and alanine transaminase) damage and of decongestion
(NTproBNP) at day 2 improved with Serelaxin adminis-
tration. These findings were consistent with the prevention
of organ damage and faster decongestion. Our study also
showed a reduction in hsTnT levels in the first days of
HF treatment in patients who were able to reduce i.v.
furosemide dose or switch it to oral route and in patients with
higher reduction in natriuretic peptides, possibly traducing
less myocardial damage in patients with more favourable
therapeutic response, that is, faster decongestion.This finding
provides additional data supporting the use of troponin as
a biomarker for ADHF severity and therefore a potential
therapeutic target. In addition, NTproBNP and hsTnT are
independent markers of increased mortality risk in HF [6,
14, 17, 18] and natriuretic peptides have shown to corre-
late with changes in ventricular wall stress, being inversely
related to the severity of left ventricular dysfunction [17,
19–21]. A decline in NTproBNP plasma levels during the
initial hospitalisation was observed in our study, a finding
consistent with previous reports [22–25]. Furthermore, this
study demonstrates that patients with hsTnT decrease have a
more pronouncedNTproBNP reduction, and a weak but pos-
itive correlation between hsTnT and NTproBNP was found.
Despite the weak correlation between hsTnT and NTproBNP,
these resultsmay suggest that congestion and ventricular wall
stress relief can be translated into natriuretic peptide and
hsTnT reduction. However, the different pathophysiological
mechanisms targeted by these biomarkers may explain the
weak correlation between them described in this study.
Nevertheless, this finding was not observed in other studies
involving patients with heterogeneous HF presentations [6,
26].
The ADHF episodes are associated with increased me-
chanical strain on the heart, activation of neurohormonal
systems, and increased and oxidative stress [25]. These
stimuli are known to mediate myocardial injury, accelerating
myocyte loss [25]. Troponin T is highly specific for cardiac
myocytes, but circulating levels may also be elevated due
to renal insufficiency. However, this mechanism does not
seem to underlie our observations, since hsTnT is positively
correlated with pCr and negatively correlated with eGFR at
day 1 and day 3, but the changes in hsTnT during treatment
are not correlated with changes in renal function. Thus,
patients with impaired renal function are likely to have higher
hsTnT levels, but hsTnT reduction is independent of renal
function changes.Thus, we believe that the elevation in hsTnT
reflects increased release from the myocardium and, thus,
may indicate myocyte injury and/or death.
In the group of patients with hsTnT increase a higher
proportion of patients with AFwere observed.These findings
are consistent with previous larger trials, in which a positive
hsTnT was detected in almost all patients with AF, with
hsTnT levels carrying strong and independent prognostic
information with a gradual increase in the risk of stroke,
cardiac, and total death [27]. Our study was underpowered
formajor cardiovascular events and death, but a longer length
of stay was observed in patients with hsTnT increase as
discussed above.
5. Limitations
Our study has several limitations that need to be considered.
It was a single-centre investigation of a small sample, which
limits our inferential analysis. The decision to withdraw
diuretic therapy was based on subjective assessment of
congestive signs and symptoms, so we cannot rule out
the interobserver variability. However, in real-life clinical
practice, the decision to step down diuretic therapy is also
based on subjective clinical evaluation. Our study protocol
defined that the first blood sample would be collected in
the first 24 h, so at the time of venous blood sampling
patients could have been treated already with diuretics.
Althoughwe are not comparing diuretic-na¨ıve patients at day
1 measurements, the overall effect of this bias would be an
underestimated difference between day 1 and day 3, which
does not significantly affect the internal validity of our study
conclusions. Finally, the external validity of our conclusions
is limited to normohypertensive and fluid overloaded HF
patients with normal ormildly impaired renal function, since
all these factors were considered inclusion criteria. On the
other hand, our conclusions can be reproducible in this set
of patients widely common in clinical practice.
6. Conclusions
Episodes of ADHF are associated with transient increases in
the blood levels of hsTnT that are reduced with effective acute
episode treatment. The decrease in hsTnT and NTproBNP
can translate ventricular wall stress relief and less myocardial
damage along with favourable ADHF treatment. Further
studies are needed to examine the value of combining
necrosis markers and natriuretic peptides in the clinical
management of ADHF patients.
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